同和药业：甲苯磺酸艾多沙班原料药通过CDE审批

Core Viewpoint - The company Tonghe Pharmaceutical has announced that its active pharmaceutical ingredient "Tafluprost" has received approval from the CDE, marking a significant milestone for its oral anticoagulant drug development [1] Group 1: Company Information - Tonghe Pharmaceutical (300636.SZ) has successfully submitted the active pharmaceutical ingredient "Tafluprost" for approval [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]